SEC Form 4 · accession 0001104659-18-047775

Nabriva Therapeutics plc · NBRV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer)

Period of report

Jul 25, 2018

Accepted (ET)

Jul 27, 2018 · 5:29 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001641640

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option^F1,F2	—	Jul 25, 2018	A	850,000	A	—	Jul 25, 2028	Ordinary Shares	850,000	850,000	D
Restricted Stock Units^F3,F4	—	Jul 25, 2018	A	150,000	A	—	Jan 31, 2020	Ordinary Shares	150,000	150,000	D

F1The exercise price is $3.53 per share.
F2The option award was granted on July 25, 2018. Vesting began on July 24, 2018 and ends on July 24, 2022. Twenty-five percent (25%) of the option award will vest on July 24, 2019, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
F3The restricted share units shall convert into ordinary shares on a one-for-one basis upon vesting of the units.
F4The restricted share units are subject to vesting as follows: 50% will vest upon certification by the board of directors of the receipt of approval by the United States Food and Drug Administration (the "FDA") of a new drug application for each of lefamulin and CONTEPO for any indication, and 50% will vest on the first anniversary of such certification by the board of directors, provided, in each case, that the registrant is performing services to Nabriva Therapeutics plc on the applicable vesting dates. If the FDA does not approve a new drug application for both lefamulin and CONTEPO by January 31, 2020, the restricted share units will terminate in full.